Finance

A short seller tweeted that Trump could crush a healthcare company, and now the stock's tanking

Read in app
Andrew Left
Andrew Left, the founder of Citron Research.  Bloomberg

On Thursday, the short-selling firm Citron Research tweeted that Express Scripts, a pharmacy benefits manager, might be targeted during the Trump administration.

"When @realdonaldtrump tells $ESRX ' you're fired' heads will roll. The culprit behind pharmaceutical price gouging. Price Target $45," the firm, which was founded by investor Andrew Left, tweeted.

The stock is now down by about 7%. In an interview with Time, President-elect Donald Trump said he thought drug-price gauging across the pharmaceutical industry was wrong, but he gave little detail about what he would do about the practice.

And that's where Express Scripts come in.

Pharmacy benefit managers manage lists called formularies for insurance companies. Those lists determine which drugs insurers will pay for and how much they'll pay. PBMs also collect a rebate from drug companies that they may or may not pass on to their clients. Those rebates are secret, as are the fees that insurers pay to the PBMs.

That lack of transparency has led critics to believe that PBMs contribute to high drug costs by taking big rebates for drugs without passing them on to customers, among other shady practices. They have some powerful enemies on Capitol Hill, too — Republican Reps. Earl "Buddy" Carter and Doug Collins, each of whom is from Georgia.

express scripts chart
Business Insider

Express Scripts is facing a lawsuit from one of its largest clients, Insurer Anthem, accusing it of self-dealing. Multiple pharmacies are also suing the company, accusing it of diverting prescriptions from them to Express Scripts' in-house mail-order pharmacy without permission. Federal investigators in New York and Massachusetts are also looking into the company.

"$ESRX is Philidor of the pharma industry," Citron also tweeted, referring to the secret pharmacy that was discovered inside battered drug company Valeant Pharmaceuticals last year. "@therealdonaldtrump promises to fix drug pricing? Two words: EXPRESS SCRIPTS."

Three PBMs dominate the market, combing for an 80% share. Of those three, Express Scripts is the largest and the only one that is not part of another company. The other two large PBMs are CVS Caremark and UnitedHealth's OptumRx.

Read next

Linette was a senior correspondent at Business Insider who focused her writing on tech, finance and economics as well as international relations. She also conducted investigations into controversial companies, like Tesla.She joined BI in the summer of 2011 after graduating from Columbia University's School of Journalism and holds a BA from Columbia University, where she finished her undergraduate education in 2008.In 2017 she won the Folio 'Rising Star' award for top women in media. In 2020 she won the 'Excellence in Financial Journalism' Award in opinion writing from NYSSCPA for a piece on US-China relations, 'The Huawei indictment marks the end of US and China's cycle of trust.' In 2023 she won the New York Press Club award for commentary in digital journalism for a series of stories about the stock market's decline in 2022.She contributes to "Marketplace," a radio show from American Public Media, and can be seen on MSNBC and CNN.Some stories by Linette: